ClinicalTrials.gg
CompletedNCT06408285Updated Oct 29, 2024

A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects

A Phase 1 interventional study of TQC3927 powder for inhalation and TQC3927 powder for inhalation placebo in Chronic Obstructive Pulmonary Disease, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.

Enrollment
12th of 17
60 · median 113
Started
2024
with 5 others
Phase 1
7 of 17
none open now
Registered
6th of 17
by date

Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 12th largest by enrollment, is one of 6 that started in 2024, is one of 7 in phase 1, and was the 6th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is a dose escalation trial. The dosing regimen involves a single-dose study. This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3927 powder for inhalation in healthy adults subjects.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily joined the study, sign form before the study and fully understand the study content;
  • Healthy subjects aged between 18 and 45 years (inclusive), both male and female;
  • The male subject should weigh at least 50kg, the female subject should weigh at least 45kg. And (BMI) within 19\~28 kg/m2;
  • Have no pregnancy plan and voluntarily take effective measures from time of screening to at least 90 days after the last dose (subjects and their partners).

Exclusion criteria

Exclusion Criteria:

  • Participated in any clinical trial within 3 months prior to the screening period;
  • Past medical history or current cardiac, breath,endocrine, metabolic, renal, hepatic, gastrointestinal, skin, infection, hematological, neurological or psychiatric diseases/abnormalities, or related chronic abnormalities, or related chronic diseases, or acute diseases, and the investigator evaluated that the subject was not suitable for the trial;
  • Individuals with a history of glaucoma, functional constipation, benign prostatic hyperplasia, urinary tract obstruction, etc;
  • People who have received or are planning to receive inactive or active vaccines during the 30 days prior to the screening period and the entire study period;
  • Current history of active tuberculosis, bronchiectasis or other non-specific lung diseases;
  • Any history of drug allergies, Individuals with a specific history of allergies or allergies;
  • Smoking more than 5 cigarettes per day or using equivalent amounts of nicotine or nicotine-containing products during the 3 months Before first administration, or those who cannot stop using any tobacco-based products during the trial;
  • Regular alcohol consumption within the first 6 months of screening (women drink more than 14 standard units per week and men drink more than 21 standard units per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) of alcohol per week during the 3 months prior to screening, or those who cannot refrain from alcohol during the trial, or those who tested positive for alcohol breath;
  • History of drug or narcotics abuse or a positive result of urine drug test at screening;
  • People who have abnormal and results in vital signs, physical examination, laboratory tests, chest radiograph and abdominal ultrasound during screening period;
  • Those who have special dietary requirements and cannot follow a unified diet;
  • Subjects Positive for Any of Virus Surface Antigen (HBsAg), Virus Antibody (Anti-HCV), Antibody (Anti-HIV), and Treponema Pallidum Antibody (Anti-TP);
  • Pregnant or lactating women or those with positive blood pregnancy test results during the screening period;
  • Subjects who are still unable to use TQC3927 inhalation powder correctly after training;
  • Any situation in which the investigator believes that this poses a safety risk to the subject in the trial or may interfere with the conduct of the study, or that the investigator believes that the subject may not be able to complete the study or may not be able to comply with the requirements of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    TQC3927 powder for inhalation

    TQC3927 powder for inhalation is administered as a single dose

    Drug: TQC3927 powder for inhalation

  • Placebo comparator
    TQC3927 powder for inhalation placebo

    TQC3927 powder for inhalation placebo is administered as a single dose

    Drug: TQC3927 powder for inhalation placebo

Interventions

  • TQC3927 is a targeted inhibitor.

  • DrugTQC3927 powder for inhalation placebo

    TQC3927 powder for inhalation placebo contains no active substance.

06

What researchers measure

Primary outcomes

  1. Adverse events (AE)

    The occurrence of all adverse events (AE).

    Time frame: From the use of the investigational drug until the last study visit, up to Day 9.

  2. Serious adverse events (SAE)

    The occurrence of all serious adverse events (SAE).

    Time frame: From the use of the investigational drug until the last study visit, up to Day 9.

  3. Abnormal security check

    The frequency, incidence, and severity of laboratory tests, vital signs, physical examinations, electrocardiogram examinations, etc.

    Time frame: From the use of the investigational drug until the last study visit, up to Day 9.

  4. Pharmacokinetics:Peak concentration (Cmax)

    The Cmax is the maximum observed plasma concentration of study drug.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  5. Area Under the Concentration-Time Curve From 0 to Last Observation (AUC [0-t])

    To characterize the pharmacokinetics of TQC3927 by assessment of area under the plasma concentration time curve from the first dose to a certain time point.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  6. Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity])

    To characterize the pharmacokinetics of TQC3927 by assessment of area under the plasma concentration time curve from 0 extrapolated to infinity.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  7. Time to reach maximum (peak) plasma concentration following drug administration (Tmax)

    To characterize the pharmacokinetics of TQC3927 by assessment of time to reach maximum plasma concentration after single and multiple dosing

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose

  8. Half-life (t1/2)

    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  9. Apparent volume of distribution(Vd/F)

    Apparent volume of distribution of the TQC3927 in plasma.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  10. Apparent clearance (CLz/F)

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  11. End elimination rate (λz)

    Derived from semi logarithmic linear regression of eliminating phase concentration points.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  12. Residual area percentage of the TQC3927 (AUC_%Extrap)

    Residual area percentage of the TQC3927 in plasma

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose

  13. Mean residence time from zero to last measurable concentration (MRT0-t)

    The average residence time from 0:00 to the last measurable concentration time point.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  14. Mean residence time from zero to infinity (MRT0-∞)

    Average residence time from 0:00 to infinity.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  15. Accumulated excretion of drugs in urine and feces (Aecum)

    Accumulated excretion of drugs in urine and feces from zero to time t.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  16. Accumulated excretion of drugs in urine (Aeu,cum)

    Accumulated excretion of drugs in urine from zero to time t.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  17. Accumulated excretion of drugs in feces(Aef,cum)

    Accumulated excretion of drugs in feces from zero to time t.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  18. Renal clearance (CLr)

    The ability of the kidneys to clear certain substances from plasma within 1 minute.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  19. Total drug excretion ratio in urine and feces (Fe%)

    The total excretion ratio of drugs in urine and feces from zero to time t.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  20. Drug excretion ratio in urine (Fe%u)

    The proportion of drug excretion in urine from zero to time t.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

  21. Drug excretion ratio in feces (Fe%f)

    The proportion of drug excretion in feces from zero to time t.

    Time frame: Single Day1: pre-dose, at 5,15,30,45 minutes,1,2,4,6,8,12,24,36,48,72 hours after-dose.

07

Study locations

1 site
  • China Japan Friendship Hospital
    Beijing, Beijing 100000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Aug 2024, 2 months.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 2 months is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 10, 2024
StartActual
May 22, 2024
Primary completionActual
Aug 19, 2024
CompletionActual
Aug 19, 2024
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06408285
Responsible party
Sponsor
First posted
May 10, 2024
Start date
May 22, 2024
Primary completion
Aug 19, 2024
Completion
Aug 19, 2024
Last update
Oct 29, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC3927

Start the discussion